• Expecting agreements to materialise
• Costs still in check
• We keep our fair value to SEK 4.23 per share

Bioextrax reported figures close to our estimates in its recent Q2 report. Revenues of MSEK 0.5 were slightly higher than expected, while costs also came in above forecast. The cash position was MSEK 3.4 higher than our estimate, mainly due to subscribed but not paid-up share capital, where a receivable of MSEK 2 was paid off during the quarter. The company made multiple advances in its projects, setting the stage for an exciting second half of the year.

Read the full report here